On October 29, METAvivor partnered with Menarini Group and Stemline to present The 4 Ws of Biomarker Testing, a powerful and informative webinar designed to demystify the role of biomarkers in metastatic breast cancer (MBC) care.
The session explored four key questions:
- What is a mutation?
- Why is biomarker testing important?
- Who should be tested?
- When should testing occur?
Sponsored by Menarini-Stemline, the webinar offered attendees actionable insights into how biomarker testing can shape the future of MBC treatment and empower patients in their care journey.
Missed the webinar? Watch the recording by clicking the button below.
About the Sponsors
Founded in 1886 in Naples and now headquartered in Florence, Italy, the Menarini Group is one of the oldest and most respected pharmaceutical companies in the world. With operations in over 140 countries and more than 17,000 employees, Menarini is known for its commitment to high-quality therapeutics, diagnostics, and innovation in patient care.
Menarini’s acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, marked its strategic entry into the U.S. oncology market. Together, they are advancing targeted therapies and diagnostics, including those relevant to ESR1 mutations in breast cancer.
